You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Using Augmented Reality To Make Cardiac Ablation Procedures Simpler and Safer

    SBC: SENTIAR, INC.            Topic: NHLBI

    TBD

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans

    SBC: INTACT GENOMICS INC            Topic: NCCIH

    PROJECT SUMMARY The economic and social burden for the treatment of chronic and infectious diseases is enormousandgt $BThe emergence of drug resistant microbesthe diminishing supply of novel classes of antibioticsand the dramatic reduction in discovery and development of anti infectiveanti proliferation and anti inflammation agents have further amplified public health concernFungi are prolific pro ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: NIEHS

    Summary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Large Pore SPP Particles for Protein Separations

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Antithrombotic Therapy with No Bleeding Risk for PCI

    SBC: APT THERAPEUTICS, INC.            Topic: y

    Adjunctive antithrombotic treatment with dual antiplatelet therapyaspirinP Yantagonistplus anticoagulantheparin or bivalirudinis a guideline mandated for percutaneous coronaryinterventionPCIpatientsDespite aggressive antithrombotic therapyhowevermyocardialperfusion after PCI remains inadequate in many patientsReocclusion from recurrent thrombosiscontinues to occurand dose limiting bleeding occurs ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Public Rights-of-Way Assessment Instrumentation to Determine Accessibility

    SBC: BENEFICIAL DESIGNS INC            Topic: 081FH2

    City planners and engineers need detailed assessments of public rights-of-way to evaluate existing conditions, determine compliance with draft accessibility guidelines, and plan reconstruction projects. Current assessment methods are inadequate and inefficient due to the time and resources required. This project will develop an automated public rights-of-way assessment process and the measuremen ...

    SBIR Phase II 2010 Department of Transportation
  9. Combination Treatment of tPA and Apyrase for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we have successfully engineered a human apyrase which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. TGF-beta Antagonists for Accelerating Wound Healing

    SBC: AUXAGEN, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Every year in the United States, gt1.25 million people suffer from burns, 6.5 million have chronic skin ulcers caused by pressure, venous stasis or diabetes mellitus and 0.25 million have keloids sufficiently severe to require surgery. Burn treatment costs 1.8 billion per year in the US. The treatment of persons with chronic skin ulcers costs 13 billion per y ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government